• Advanced Biomed posted a net loss of US$488,942 for the three months ended March 31, 2026, narrowing from US$1,383,874 a year earlier.
• Total operating expenses fell 8% to US$519,836, with general and administrative costs down 20% at US$276,610 while research and development spending rose 11% to US$243,226.
• Other income swung to income of US$30,894 from an expense of US$629,992 a year earlier, reflecting an exchange gain of US$31,006 versus an exchange loss in the prior-year quarter.
• For the nine months ended March 31, 2026, results swung to net income of US$5.98 million from a net loss of US$2.56 million, driven by a US$7.35 million gain on disposal of subsidiaries.
• Subsequent to quarter-end, the company agreed to acquire Acellent Technologies (Hong Kong) Co. Limited in a 270,000-share deal, positioning a pivot toward AI-powered financial audit solutions, and also took a US$600,000 unsecured six-month loan at 10% interest.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Advanced Biomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-057226), on May 15, 2026, and is solely responsible for the information contained therein.